https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2001-09-01 / Eur. J. Cancer 2001 Sep;37(13):1599-608
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2001-09-01 / Eur. J. Cancer 2001 Sep;37(13):1599-6082001-09-01 00:00:002001-09-01 00:00:00Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2001-07-01 / Eur. J. Cancer 2001 Jul;37(11):1429-34
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2001-07-01 / Eur. J. Cancer 2001 Jul;37(11):1429-342001-07-01 00:00:002019-02-15 08:39:25Enhancement of the therapeutic outcome of radio-immunotherapy by combination with whole-body mild hyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2001-07-01 / Semin. Hematol. 2001 Jul;38(3):260-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2001-07-01 / Semin. Hematol. 2001 Jul;38(3):260-72001-07-01 00:00:002019-02-15 08:51:13Immunotherapy of multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2001-06-26 / Proc. Natl. Acad. Sci. U.S.A. 2001 Jul;98(15):8809-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2001-06-26 / Proc. Natl. Acad. Sci. U.S.A. 2001 Jul;98(15):8809-142001-06-26 00:00:002019-02-15 08:39:02Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2001-06-21 / MMW Fortschr Med 2001 Jun;143(25):28-32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2001-06-21 / MMW Fortschr Med 2001 Jun;143(25):28-322001-06-21 00:00:002019-02-15 09:17:56[Addition of hyperthermia. Heat potentiates cancer therapy]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2001-06-01 / Lancet Oncol. 2001 Jun;2(6):343-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2001-06-01 / Lancet Oncol. 2001 Jun;2(6):343-532001-06-01 00:00:002019-02-15 08:44:53The use of dendritic cells in cancer therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2001-05-01 / J. Neurooncol. 2001 May;53(1):39-46
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2001-05-01 / J. Neurooncol. 2001 May;53(1):39-462001-05-01 00:00:002001-05-01 00:00:00Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2001-05-01 / Eur. J. Immunol. 2001 May;31(5):1602-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2001-05-01 / Eur. J. Immunol. 2001 May;31(5):1602-92001-05-01 00:00:002019-02-15 09:18:06The role of heat shock protein (hsp70) in dendritic cell maturation: hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2001-05-01 / Int. J. Oncol. 2001 May;18(5):945-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2001-05-01 / Int. J. Oncol. 2001 May;18(5):945-522001-05-01 00:00:002020-06-23 09:45:33Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2001-05-01 / Lung Cancer 2001 May;32(2):197-201
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2001-05-01 / Lung Cancer 2001 May;32(2):197-2012001-05-01 00:00:002001-05-01 00:00:00Localised spontaneous regression in mesothelioma — possible immunological mechanism
